GNV069

GNV069 is a small interfering RNA (siRNA) therapeutic conjugated with N-acetylgalactosamine (GalNAc), currently in late preclinical development by Genevant Sciences for the treatment of liver fibrosis. The drug utilizes Genevant's proprietary ligand-mediated delivery platform, which employs GalNAc conjugation to target the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes, ensuring efficient and specific delivery to the liver. By leveraging the RNA interference (RNAi) pathway, GNV069 is designed to silence the expression of a specific, though currently undisclosed, gene involved in the pathogenesis of liver fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins. Genevant is actively seeking partnering opportunities for the further clinical development and commercialization of this candidate.